We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+6.08%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$42.8B
AUM Growth
+$3.35B
(+8.5%)
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
3.15%
Top 10 Holdings %
Top 10 Hldgs %
14.82%
Holding
2,894
New
39
Increased
2,631
Reduced
168
Closed
44
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Abbott
ABT
|
+$21.8M |
| 2 |
Chevron
CVX
|
+$20.5M |
| 3 |
Berkshire Hathaway Class B
BRK.B
|
+$19.7M |
| 4 |
Incyte
INCY
|
+$17.8M |
| 5 |
ExxonMobil
XOM
|
+$16.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SE
Spectra Energy Corp Wi
SE
|
+$49.6M |
| 2 |
STJ
St Jude Medical
STJ
|
+$41.1M |
| 3 |
LLTC
Linear Technology Corp
LLTC
|
+$30.3M |
| 4 |
HAR
Harman International Industries
HAR
|
+$13.8M |
| 5 |
ENH
Endurance Specialty Holdings Ltd
ENH
|
+$10.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.2% |
| 2 | Technology | 15.06% |
| 3 | Healthcare | 13.05% |
| 4 | Industrials | 10.88% |
| 5 | Consumer Discretionary | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
STRP
2376
DELISTED
Straight Path Communications Inc.
STRP
| $386K | ﹤0.01% |
10,731
+257
| +2% | +$8.91K |
|
2377
America's Car Mart
CRMT
$26.1M
| $385K | ﹤0.01% |
10,575
-228
| -2% | -$8.76K |
|
|
SIOX
2378
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $385K | ﹤0.01% |
3,223
+114
| +4% | +$11.9K |
|
2379
CVR Energy
CVI
$3.59B
| $381K | ﹤0.01% |
18,969
+63
| +0.3% | +$1.39K |
|
|
PRTK
2380
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $379K | ﹤0.01% |
19,713
+2,270
| +13% | +$35.8K |
|
|
TRR
2381
DELISTED
Trc Companies
TRR
| $379K | ﹤0.01% |
21,722
+2,472
| +13% | +$26.6K |
|
|
FGL
2382
DELISTED
Fidelity & Guaranty Life
FGL
| $379K | ﹤0.01% |
13,627
+559
| +4% | +$14.4K |
|
2383
CytomX Therapeutics
CTMX
$686M
| $378K | ﹤0.01% |
21,910
+872
| +4% | +$11.5K |
|
2384
DHI Group
DHX
$178M
| $378K | ﹤0.01% |
95,773
+26,502
| +38% | +$137K |
|
|
GPX
2385
DELISTED
GP Strategies Corp.
GPX
| $378K | ﹤0.01% |
14,949
+468
| +3% | +$12K |
|
2386
Akebia Therapeutics
AKBA
$349M
| $377K | ﹤0.01% |
40,992
+1,266
| +3% | +$12.4K |
|
2387
Old Second Bancorp
OSBC
$1.28B
| $377K | ﹤0.01% |
33,526
+1,243
| +4% | +$13.4K |
|
2388
The RMR Group
RMR
$327M
| $377K | ﹤0.01% |
7,615
+68
| +0.9% | +$3.23K |
|
|
REV
2389
DELISTED
Revlon, Inc.
REV
| $376K | ﹤0.01% |
13,513
+544
| +4% | +$17.3K |
|
|
CHCT
2390
Community Healthcare Trust
CHCT
$527M
| $375K | ﹤0.01% |
15,710
+1,288
| +9% | +$29.4K |
|
2391
First Bancorp
FNLC
$394M
| $375K | ﹤0.01% |
13,766
+480
| +4% | +$13.3K |
|
|
ALTA
2392
DELISTED
Altabancorp
ALTA
| $374K | ﹤0.01% |
14,126
+608
| +4% | +$15.8K |
|
2393
Marcus & Millichap
MMI
$1.16B
| $373K | ﹤0.01% |
15,158
+433
| +3% | +$11.2K |
|
|
ENZ
2394
DELISTED
Enzo Biochem, Inc.
ENZ
| $373K | ﹤0.01% |
44,532
+1,762
| +4% | +$12.4K |
|
2395
Miller Industries
MLR
$572M
| $371K | ﹤0.01% |
14,072
+519
| +4% | +$13.3K |
|
2396
Varonis Systems
VRNS
$4.56B
| $369K | ﹤0.01% |
34,824
+1,200
| +4% | +$11.5K |
|
|
EMWP
2397
DELISTED
Eros Media World PLC
EMWP
| $369K | ﹤0.01% |
1,794
+134
| +8% | +$30.5K |
|
2398
AMES National
ATLO
$270M
| $368K | ﹤0.01% |
12,010
+202
| +2% | +$6.44K |
|
2399
Culp Inc
CULP
$45.1M
| $368K | ﹤0.01% |
11,797
-132
| -1% | -$4.35K |
|
|
BRG
2400
DELISTED
Bluerock Residential Growth REIT, Inc.
BRG
| $368K | ﹤0.01% |
29,916
+6,108
| +26% | +$77.9K |
|
Similar funds
VAM
RhumbLine Advisers's Q1 2017 Portfolio in Review
As of Q1 2017, RhumbLine Advisers held 2,894 positions worth $42.8B, up 8.5% from $39.5B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
RhumbLine Advisers deployed $1.35B of net new capital in Q1 2017, opening 39 new positions and adding to 2,631 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
By sector, the portfolio is most concentrated in Financials at 16% of assets, down from 17% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Biogen, an estimated $8.21M trimmed.
- RhumbLine Advisers's largest Q1 2017 buy was Bioverativ Inc. Common Stock: 197,812 shares worth $10.8M.
- RhumbLine Advisers added most to Abbott in Q1 2017, an estimated $21.8M increase.
- RhumbLine Advisers's biggest Q1 2017 reduction was Biogen, cutting an estimated $8.21M.
- RhumbLine Advisers fully exited Spectra Energy Corp Wi in Q1 2017, selling an estimated $49.6M.
- RhumbLine Advisers's ten largest holdings make up 15% of its $42.8B portfolio in Q1 2017.
- RhumbLine Advisers opened 39 new positions and closed 44 in Q1 2017.
- RhumbLine Advisers's portfolio value rose 8.5% quarter-over-quarter to $42.8B.
Based on RhumbLine Advisers's 13F filing for Q1 2017, filed 2 May 2017.